Form 4: Amicus Therapeutics CEO Bradley Campbell Executes Stock Options and Sells Shares
SEC Form 4 Filing
Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold shares on June 3, 2024, according to a recent SEC Form 4 filing.
Summary
- On June 3, 2024, Bradley L Campbell, the President and CEO of Amicus Therapeutics, exercised stock options to acquire 7,500 shares of common stock at a price of $8.61 per share.
- Simultaneously, Campbell sold 7,500 shares of common stock at $10 per share.
- Following these transactions, Campbell directly owns 886,654 shares of Amicus Therapeutics common stock.
- He also holds options to purchase 45,000 shares.
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 23, 2023.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There's no inherent positive or negative signal.
Industry Context
Executive stock transactions are common and are closely watched by investors for signals about a company's prospects. A pre-arranged trading plan like Rule 10b5-1 helps executives avoid accusations of insider trading.
Key Dates
| Date | Description |
|---|---|
| 08/23/2023 | Date of adoption of Rule 10b5-1 trading plan |
| 06/03/2024 | Date of stock option exercise and share sale |
| 06/05/2024 | Date of Form 4 filing |
| 01/02/2025 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.